Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
NCT04561557 · Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder
RecruitingAntibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main pathogenic mechanism. In the immune response, pathogenic antibodies acting on autoantigens of the nervous system are collectively referred to as autoantibodies of the nervous system, and antibody-mediated inflammatory diseases of the nervous system can occur in the central nervous system, peripheral nervous system, and neuromuscular junctions, and muscles. In this study, we will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathyand (IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) and POEMS Syndrome. B-cell maturation antigen (BCMA) is expressed on the surface of plasma cells, thus making it an ideal target for targeted therapies. Chimeric antigen receptor (CAR) T cells against BCMA offers another potential therapeutic option to eliminate plasma cells in patients with neurological autoimmune diseases driven by abnormal antibody who still suffer recurrent attacks from conventional treatments. In the current study, the safety and efficacy of a novel CAR-T cell therapy using CT103A cells, are evaluated in patients with relapsed/refractory antibody-mediated idiopathic inflammatory diseases.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 75 Years
WhereWuhan, Hubei, China
SponsorTongji Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
NCT04106830 · NMO Spectrum Disorder, MRI,
Multiple Sclerosis RecruitingCLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI/T2WI/FLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.
Phase—
TypeObservational
Age16 Years – 75 Years
WhereBeijing, Beijing Municipality, China
SponsorBeijing Tiantan Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
NCT06256575 · Scleroderma, Systemic, Digital Ulcer
RecruitingThis study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.
PhaseNA
TypeInterventional
Age18 Years
WhereCalgary, Alberta, Canada + 4 more
SponsorPrimus Pharmaceuticals
▾Tap for detailsClick for full details — eligibility, all locations, contacts Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research
NCT04906928 · Spinal Cord Injuries
Recruiting* verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence. * 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)
Phase—
TypeObservational
Age18 Years
WhereParis, France
SponsorFondation Ophtalmologique Adolphe de Rothschild
▾Tap for detailsClick for full details — eligibility, all locations, contacts National Registry of Rare Kidney Diseases
NCT06065852 · Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis
RecruitingThe goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: * Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. * Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. * Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.
Phase—
TypeObservational
AgeAny
WhereBristol, South West, United Kingdom
SponsorUK Kidney Association
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RecruitingA Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
PhasePhase 1
TypeInterventional
Age18 Years – 65 Years
WherePalo Alto, California, United States
SponsorStanford University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Eccentric Exercise and Fatigue in Multiple Sclerosis
NCT06505421 ·
Multiple Sclerosis, Fatigue
RecruitingThe goal of this observational study is to compare the impact of eccentric resistance training to traditional resistance training on fatigue in persons with multiple sclerosis (MS). The primary question this study is asking is the following: is eccentric resistance training more fatiguing than traditional resistance training in persons with MS?. Participants will be asked to come for two sessions for two weeks. In the first week, subjects will undergo a bout of either traditional or eccentric resistance training. The next day they will return to assess their level of fatigue. The following week the subject will return and undergo whatever type of training they did not experience the first week, and it's effects on fatigue will again be assessed. The difference between the subjects level of fatigue for either condition will be compared.
Phase—
TypeObservational
Age18 Years – 75 Years
WhereNew York, New York, United States
SponsorHunter College of City University of New York
▾Tap for detailsClick for full details — eligibility, all locations, contacts Home Based Infusions for Ocrelizumab
RecruitingThe goal is to assess the safety and effectiveness of home ocrelizumab infusion.
PhasePhase 4
TypeInterventional
Age18 Years – 55 Years
WhereCentennial, Colorado, United States
SponsorUniversity of Colorado, Denver
▾Tap for detailsClick for full details — eligibility, all locations, contacts CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT07305116 · Autoimmune Diseases,
Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome
RecruitingCAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
PhasePhase 1
TypeInterventional
Age3 Years
WhereHangzhou, Zhejiang, China
SponsorThe Children's Hospital of Zhejiang University School of Medicine
▾Tap for detailsClick for full details — eligibility, all locations, contacts PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RecruitingThe purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereScottsdale, Arizona, United States + 21 more
SponsorPhenoNet, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
NCT06788886 · Malignant Brain Neoplasm, Malignant Solid Neoplasm,
Multiple Sclerosis RecruitingThis clinical trial studies the effect of respiratory training for enhancing brain and mental health among patients with multiple sclerosis (MS) and cancer (along with their caregivers). The relationship between respiration, cardiovascular effects in the brain, mental health, and neurophysiological mechanisms are significant for patient populations facing complex health challenges, such as those with cancer and neurodegenerative disease, and their caregivers. By measuring oxygen delivery to brain tissues and cerebrospinal fluid flow, this trial may help researchers investigate the potential benefits of respiratory training for patients with MS and cancer and their caregivers.
PhaseNA
TypeInterventional
Age18 Years – 85 Years
WhereRochester, Minnesota, United States
SponsorMayo Clinic
▾Tap for detailsClick for full details — eligibility, all locations, contacts A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
RecruitingThis is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.
Phase—
TypeObservational
Age18 Years – 100 Years
WhereAlbstadt, Baden-Wurttemberg, Germany + 145 more
SponsorNovartis Pharmaceuticals
▾Tap for detailsClick for full details — eligibility, all locations, contacts Vancomycin Study in Multiple Sclerosis (MS)
RecruitingThe overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.
PhasePhase 1
TypeInterventional
Age18 Years – 50 Years
WhereNew York, New York, United States
SponsorIcahn School of Medicine at Mount Sinai
▾Tap for detailsClick for full details — eligibility, all locations, contacts tdCS Combined With Treadmill Training in Patients With Multiple Sclerosis
NCT06986278 · tDCS, Sham tDCS
RecruitingThis clinical trial aims to evaluate the therapeutic effectiveness of transcranial direct current stimulation (tDCS), a non-invasive technique that modulates cortical excitability, in combination with gait training in patients with multiple sclerosis (MS). The study focuses on improving balance and walking ability, which are commonly impaired in this population. A randomized, triple-blind, controlled design will be used, comparing an active tDCS group with a sham stimulation group, both receiving the same gait training protocol. Outcomes will include functional and clinical measures related to mobility, balance, and fatigue. The project builds on previous meta-analytical evidence suggesting positive effects of tDCS in MS and aims to confirm these findings using an optimized stimulation protocol.
PhaseNA
TypeInterventional
Age18 Years
WhereToledo, Toledo, Spain + 1 more
SponsorUniversity of Castilla-La Mancha
▾Tap for detailsClick for full details — eligibility, all locations, contacts Reliability and Validity of the Turkish Version of General Sleep Disturbance Scale (GSDS-T) in Multiple Sclerosis
NCT06875908 ·
Multiple Sclerosis, Sleep Disturbance
RecruitingThe GSDS-T was developed by Lee KA to assess difficulty falling asleep, waking up during sleep, sleep quality, and daytime alertnes. The Turkish validity and reliability of the scale have been conducted on stroke patients but not on multiple sclerosis patients. The aim of this study is to investigate the validity and reliability of the Turkish version of general sleep disturbance scale (GSDS-T) in patients with multiple sclerosis
Phase—
TypeObservational
Age18 Years – 65 Years
WhereBağcılar, Istanbul, Turkey (Türkiye)
SponsorIstanbul Medeniyet University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity
RecruitingThe study aimed to explore the link between urinary incontinence (UI) severity in patients with multiple sclerosis (PwMS), electromyography (EMG) findings, and other relevant factors.
Phase—
TypeObservational
Age30 Years – 50 Years
WhereIstanbul, Turkey (Türkiye)
SponsorArtvin Coruh University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
RecruitingThe purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
PhasePhase 2
TypeInterventional
Age18 Years – 70 Years
WhereBirmingham, Alabama, United States + 60 more
SponsorCelgene
▾Tap for detailsClick for full details — eligibility, all locations, contacts Skeletal Muscle Aging and Responsiveness in Aged People With MS
NCT07500727 ·
Multiple Sclerosis, Aging
RecruitingThe purposes of this study are to: 1) compare baseline muscle and cardiovascular health in older individuals (\>60 years old) diagnosed with MS to age-matched people without MS, 2) determine muscle and whole body changes to an exercise training program, 3) determine if the muscle in a more affected leg in individuals diagnosed with MS is different from the muscle of a less affected leg, and 4) if or how individuals diagnosed with MS adapt differently than age-matched people without MS to exercise training. Participation in this study will average 1.5 hours per visit, 3 visits per week, for approximately 4 months.
PhaseNA
TypeInterventional
Age60 Years
WhereOklahoma City, Oklahoma, United States
SponsorOklahoma Medical Research Foundation
▾Tap for detailsClick for full details — eligibility, all locations, contacts The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis
RecruitingIt is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients. 80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.
PhaseNA
TypeInterventional
Age18 Years – 60 Years
WhereBarcelona, Barcelona, Spain
SponsorHospital Universitari Vall d'Hebron Research Institute
▾Tap for detailsClick for full details — eligibility, all locations, contacts REtinal Markers In Neuroinflammatory Diseases ("REMIND")
NCT06369766 ·
Multiple Sclerosis, Neuroinflammatory Diseases
RecruitingThe goal of this observational study, including patients with Multiple Sclerosis, patients with other neuroinflammatory diseases and healthy controls, is to determine the predictive value of retinal markers in predicting disease progression. Participants complete a questionnaire and undergo various non-invasive retinal routine clinical examinations.
Phase—
TypeObservational
Age18 Years
WhereBasel, Switzerland
SponsorUniversity Hospital, Basel, Switzerland
▾Tap for detailsClick for full details — eligibility, all locations, contacts